KMT2A and leukemia: BCL2 was highly expressed in MLL fusion-mediated leukemia (Figure 5—figure supplement 2A,B), and many human MLL fusion leukemia cell lines were sensitive to a BCL-2 inhibitor (i.e. ABT-199)(Pan et al., 2014).